State Street Corporation/ US8574771031 /
2024-04-25 10:10:00 PM | Chg. -1.00 | Volume | Bid1:30:42 PM | Ask1:30:42 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
73.29USD | -1.35% | 5.84 mill. Turnover: 354.51 mill. |
72.92Bid Size: 300 | 74.04Ask Size: 100 | 22.13 bill.USD | 3.60% | 12.97 |
GlobeNewswire
6:27 AM
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
GlobeNewswire
04-25
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
GlobeNewswire
04-24
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise o...
GlobeNewswire
04-24
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Sh...
GlobeNewswire
04-23
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shar...
GlobeNewswire
04-18
INVESTIGATION ALERT: Edelson Lechtzin LLP is Investigating Globe Life Inc. (NYSE: GL) and Encourages...
GlobeNewswire
04-15
Blue World Acquisition Corporation Postponed the Extraordinary General Meeting to Approve the Busin...
GlobeNewswire
04-10
DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of Group Health Cooperativ...
GlobeNewswire
04-09
DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of Customers Whose Persona...
GlobeNewswire
04-05
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Customers Whose Persona...
GlobeNewswire
04-05
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Customers Whose Persona...
GlobeNewswire
03-25
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
GlobeNewswire
03-20
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
GlobeNewswire
03-19
EVVTY INVESTOR ALERT: Edelson Lechtzin LLP Reminds Evolution AB (publ) (OTC: EVVTY) Shareholders Abo...
GlobeNewswire
03-19
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Pla...